Arbutus Biopharma Corp Line of Credit Facility, Maximum Borrowing Capacity
Arbutus Biopharma Corp (ABUS) had Line of Credit Facility, Maximum Borrowing Capacity of $3.00 million as of 2012-12-31, per its 20-F filed 2013-03-27.
Discontinued › Notes › Debt
us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity · last filed 2013-03-27
- 2011-12-31: Line of Credit Facility, Maximum Borrowing Capacity 3.05M CAD.
- 2011-12-21: Line of Credit Facility, Maximum Borrowing Capacity 3.05M CAD.
CAD
| Period end | Line of Credit Facility, Maximum Borrowing Capacity |
|---|---|
| 2011-12-31 | 3.05M CAD 20-F · filed 2013-03-27 |
| 2011-12-21 | 3.05M CAD 20-F · filed 2013-03-27 |
USD
| Period end | Line of Credit Facility, Maximum Borrowing Capacity |
|---|---|
| 2012-12-31 | $3.00M 20-F · filed 2013-03-27 |
| 2011-12-31 | $3.00M 20-F · filed 2013-03-27 |
| 2011-12-21 | $3.00M 20-F · filed 2013-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |